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CASE PRESENTATION
Patient 1. A 58-year-old man was hospitalized with hypertension,
168/114 mm Hg, congestive heart failure secondary to fluid retention, and
a serum creatinine of 6.9 mgldl. Six years earlier he had received a cardiac
transplant for end-stage idiopathic cardiomyopathy and was given cyclo-
sporine (CsA). Prior to transplantation he was normotensive (blood
pressure, 100/70 mm Hg) and had a serum creatinine concentration of 3.6
mg/dl, which was attributed to his refractory biventricular heart failure. He
gave no family history for renal disease or high blood pressure. The serum
creatinine decreased to 0.8 mg/dl one month after cardiac transplantation
and fluctuated between 1 to 2 mg/dl for about four years before beginning
an inexorably upward course. His blood pressure rose rapidly after
transplantation, reaching 160/120 mm Hg by the second month.
Four months before this admission, he had been evaluated for rapid
deterioration in renal function and refractory hypertension; his blood
pressure reached as high as 180/140 mm Hg. A percutaneous renal biopsy
was obtained. An endomyocardial biopsy at the same time revealed no
evidence of rejection. During this admission, acute dialysis was initiated,
and thc patient's congestive heart failure improved markedly following a
10-liter fluid removal. He subsequently was maintained on chronic dialysis
with continued good cardiac graft function.
Patient 2. A 6-year-old girl first developed steroid-dependent nephrotic
syndrome at age 26 months. A renal biopsy at 33 months showed
minimal-change disease and normal juxtaglomerular apparatus (JGA, Fig.
1A). A chlorambucil-induced remission of eight weeks was followed by a
relapse two months after the drug was discontinued. Her nephrotic
syndrome became resistant to oral corticosteroid administration, respond-
ing only to intravenous methyiprednisolone.
yclosporine (10—12 mg/kg/day), given in divided doses at eight-hour
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intervals, was started at age 41 months. A repeat renal biopsy at age 52
months confirmed the initial diagnosis of minimal-change disease and
mild JGA enlargement (Fig. 1B). She remained symptom-free during a
14-month course of CsA monotherapy. Thereafter, her nephrotic syn-
drome recurred and became resistant to intravenous methyiprednisolone.
Four monthly intravenous doses of cyclophosphamide (1 g/m2/dose) also
produced no response. Her other medications at the time included
enalapril, diltiazem, furosemide, spironolactone, metolazone, and ferrous
sulfate.
At age 63 months, and after 9 months of persistent nephrotic syndrome,
she was given a second course of CsA, this time for 25 months: Concom-
itantly she received intravenous methylprednisolone and alternate-day
oral prednisone (the Mendoza protocol [1]). She remained in complete
remission during this entire period. Her growth normalized, as did her
serum albumin. Serum creatinine ranged from 0.2 to 0.5 mg/dl; the
calculated GFR [2] was 73—95 ml/min/1.73 m2. At age 75 months, 12
months into the second course of CsA, a third renal biopsy demonstrated
further enlargement of the JGA (Fig. IC). The patient maintained an
average blood pressure of 90/60 mm Hg before, during, and after CsA
therapy. Enalapril was given for its antiproteinuric effect and diltiazem for
its ability to reduce CsA clearance and dosage, and thus, cost.
Renal biopsy
DR. ARTHUR H. COHEN (Renal Pathologist, Cedars-Sinai Medical Center,
and Professor of Pathology and Medicine, UCLA School of Medicine, Los
Angeles, California): Pathologic examination of the biopsy specimen from
Patient 1 revealed arterial intimal fibrosis, arteriolar insudative lesions
(hyalinization), extensive tubular atrophy with interstitial fibrosis, com-
plete and segmental glomeruloscierosis, and enlargement of the JGA.
These changes, in aggregate, clearly indicate severe nephrosclerosis;
however, the JGA enlargement, probably out of proportion to the other
changes, suggests a component of chronic CsA toxicity.
Light microscopy of the first biopsy from Patient 2 revealed glomeruli of
normal size and morphology, no tubular or interstitial changes, and no
abnormalities of the arteries or arterioles. The JGA was not enlarged or
otherwise abnormal (Fig. IA). Glomeruli were negative by immunofluo-
rescence; ultrastructural examination disclosed complete effacement of
foot processes as the sole structural alteration. The second biopsy,
following 11 months of CsA therapy, was characterized by glomeruli with
the same appearance as earlier. The specimen contained a few scattered
atrophied tubules. The JGA was mildly enlarged (Fig. 1B). Thus, the
features of minimal-change disease persisted, along with an increase in the
size of the JGA. This latter finding is observed in chronic CsA toxicity. The
third biopsy, performed after 12 months of a second course of CsA, was
characterized by several zones ("stripes") of tubular atrophy and intersti-
tial fibrosis (Fig. 1D), few (10%) glomeruli with some ischemic capillary
wall wrinkling (Fig. 1E), and moderate enlargement of the JGA (Fig. 1C).
Ultrastructural examination revealed partial (70%) effacement of glomer-
ular visceral epithelial cell foot processes and increased protogranules and
mature granules in cells of the JGA.
In short, renal biopsy reveals the structural changes associated with
chronic CsA administration: chronic ischemic changes, including varying
degrees of glomerular capillary wall wrinkling, tubular atrophy with
interstitial fibrosis in a vascular arterial distribution ("striped fibrosis"),
normal arteries, and enlargement of the JGA. There also can be necrosis/
degeneration of arteriolar smooth muscle and plasma protein insudative
lesions in arteriolar walls, typically in an adventitial location; these findings
are termed CsA-associated arteriolopathy [3].
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Fig. 1. Renal biopsy findings, Patient 2. First biopsy. A. The glomeruli, tubules, interstitium, and juxtaglomerular apparatus all are unremarkable.
(Periodic acid-methenamine silver, x 195). Second biopsy: B. The only abnormality is the mildly enlarged juxtaglomerular appartus (arrow). (Masson's
trichrome, X 195). Third biopsy: C. Stripe of tubular atrophy and interstitial fibrosis separates a normal glomerulus (arrow) from an ischemic one (double
arrows). (Periodic acid-methenamine silver, >< 45). D. Normal and ischemic glomcruli, with portion of normal artery at the left border. (Periodic
acid-methenamine silver, X 195). E. Vascular pole of glomerulus with enlarged juxtaglomerular apparatus. (Periodic acid-methenamine silver, )< 295).
DISCUSSION these two patients. Patient 1, the heart transplant recipient,
DR. DAVID B. N. LEE (chief Nephrolo' Section, Department of initially had normal blood pressure and normal renal function, as
Veterans Affairs Medical Center, Sepulveda, and UCLA-San Fer- reflected by the serum creatinine concentration of 0.8 mg/dl
nando Valley Medical Program, Sepulveda and Sylmar; and Profes-. immediately after the restoration of normal cardiac function. He
sor of Medicine, UCLA School of Medicine, Los Angeles, Galifor- had no family history of hypertension or renal disease. His CsA
nia): Thank you, Dr. Cohen. Let me first summarize the course of dosage was tapered to 5 mg/kg/day at about 10 weeks after
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System component Animals Humans
Plasma renin activity (PRA) a (Pattern I) . (Pattern II)
Plasma toal renin and pro-renin
Renin synthesis and secretion
1 1'
NS'
Renin processing and secretory defects + +
JGA hypertrophy and hyperplasia + +
Recruitment of renin-containing cells + NS
Tissue and plasma ACE activity C) NS
AT1 receptor density C) NS
transplantation and thereafter was maintained at 1—3 mg/kg/day.
His postoperative course was characterized by the rapid develop-
ment of hypertension and progressive loss of renal function, which
culminated in end-stage renal failure and chronic hemodialysis six
years later. The heart graft remained free of rejection and
maintained good function. The second patient, a 6-year-old girl,
was given CsA for minimal-change nephrotic syndrome, which
was initially steroid-dependent and subsequently steroid-resistant.
In contrast to the first patient, she was given high doses of CsA—as
much as 17 mg/kg/day—but her blood pressure and renal function
remained stable throughout the cumulative treatment period of
39 months. Serial renal biopsies, however, demonstrated progres-
sive structural changes attributable to CsA administration (Fig. 1).
These two patients illustrate the serious hypertensive [4] and
nephrotoxic 15] effects of CsA. However, individual susceptibility
to the toxic effects of CsA varies. For example, children appear to
tolerate higher CsA dosage. This difference has been attributed to
the presence in children of a less efficient CsA absorptive process
and a more efficient CsA metabolic process than those in adults
[6]. The relatively low plasma CsA level, in the face of high-dose
CsA administration in our younger patient, is consistent with such
a postulate. The second case also reminds us that marked
structural damage in the kidney can occur in the absence of overt
clinical evidence of hypertension or nephrotoxicity.
Finally, both patients exhibited hypertrophy and hyperplasia of
the juxtaglomerular apparatus, and this observation leads us to
the focus of this Forum. In the nephrotic child, serial biopsies
demonstrated JGA enlargement only after the initiation of CsA
therapy; sustained CsA treatment exaggerated this enlargement.
This finding is a well-recognized feature of CsA administration in
patients [7—9] and rats [10—12]. However, because plasma renin
activity (PRA) is either normal or low in humans taking CsA [13,
14], the renin-angiotensin system (RAS) has not been considered
important in the pathogenesis of CsA hypertension [4] and
nephrotoxicity [5].
This Forum will address the complex interactions between CsA
and the RAS and the possible role of the renin axis in the
pathogencsis of CsA hypertension and nephrotoxicity. I do not
suggest that CsA causes hypertension and ncphrotoxicity solely
through its action on the RAS. Rather, I will summarize evidence
supporting RAS as one importants participant in the pathogenesis
of these two complications of CsA administration.
Effect of CsA on the RAS
Cyclosporine has a variety of effects on the renin-angiotensin
system (Table 1). In virtually all animal studies done by our group
and others, CsA increases PRA [13, 15, 16]. Although most of
these have been rat studies, CsA also stimulates PRA in the dog
[17]. In-vitro, studies using renal cortical slices suggest that CsA
directly stimulates renin release [18, 19]. Using rat juxtaglomeru-
lar cell culture, Kurtz, Bruna, and Kuhn concluded that CsA not
only increases reniri secretion, as reflected by increases in renin
activity in the incubation medium, but also stimulates its synthesis
[20]. This stimulatory action is dose-dependent and rapid in onset:
CsA produces a secretory response within 10 minutes and a
synthetic response by 24 hours. In addition to direct stimulation of
renin secretion and synthesis in juxtaglomerular cells in vitro, CsA
also is associated with juxtaglomerular hypertrophy and hyperpla-
sia in vivo [10—12]. Using immunocytochemistry, Tufro-McRed-
die and associates demonstrated increased renin-staining cells in
the JGA and recruitment of renin-containing cells in the afferent
arterioles of rats treated with CsA for three weeks [21]. These
authors noted that CsA altered neither the level nor the distribu-
tion of intrarenal renin mRNA and suggested that CsA acts on
renal renin metabolism through post-transcriptional events. This
report contrasts with short-term (up to 24 hours) in-vitro studies,
which clearly demonstrated a direct CsA-induced stimulatory
effect on renin synthesis in juxtaglomerular cells [20].
The mechanism by which CsA activates the renin-angiotensin
system is not known. Acute incubation studies demonstrated that
CsA's effect on reniri is not mediated by changes in cellular
prostaglandin or cAMP [20]. The estimated half-maximal effect
on renin secretion and production was iO M, a value approxi-
mating the dissociation constant for CsA binding to cyclophilin,
2 x iO M. This observation suggests that CsA-cyclophilin
binding is involved in the activation of the renin axis. Cyclosporine
H (CsH), which differs from CsA in one amino acid at position 11,
binds cyclophilin weakly and has no effect on juxtaglomerular cell
renin secretion [20].
After giving rats CsA (12.5 mg/kg/day for three weeks), Shehata
and associates detected selective accumulation of platelet-derived
growth factor (PDGF) within the enlarged secretion granules of
the hypertrophied juxtaglomerular cells [12]. The same laboratory
also observed increased transforming growth factor-/3 (TGF-/3) in
juxtaglomerular cells of CsA-treated rats [22]. Transforming
growth factor-p stimulates renin secretion by juxtaglomerular
cells [23]. Are these growth-regulatory factors responsible for
RAS activation, JG cell hypertrophy and hyperplasia, or both?
Also, angiotensin II (Ang II) stimulates the synthesis of both
PDGF [24] and TGF-13 [25, 26]; does CsA therefore activate these
factors directly, or indirectly by stimulating the RAS? Clearly
these and many other questions await resolution.
Cyclosporine also acts on other components of the RAS. Our
laboratory has reported a dramatic elevation in plasma pro-renin
concentration in rats treated with CsA for two weeks [19]. Erman
and colleagues reported that angiotensin-converting enzyme
(ACE) activity was stimulated in the lung and serum, but reduced
in renal cortex, in rats given CsA [27]. Two studies have investi-
gated the effect of CsA on type-I angiotensin receptor (AT1).
Tufro-McReddie and coworkers found that CsA reduced renal
AT1 receptor mRNA levels [21]; Regitz-Zagrosek and associates
noted a CsA-induced increase in the number of AT1 receptors in
rat kidney, liver, and adrenal cortex and medulla [28]. Simulta-
neous treatment with the AT1 antagonist losartan (DUP 753)
aborted this CsA-induced upregulation.
In most respects, cyclosporine's effects are similar in animals
and humans (Table 1). The exception is CsA's action on PRA. In
contrast to findings in animal studies, CsA fails to increase [29,
Table 1. Cyclosporine and the renin-angiotensin system
Symbols: 1., decreases; 1' increases; +, induces; C) modulates.
Not studied.
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30], and in most instances decreases [8, 31], PRA in human studies
[13]. Nor does cyclosporine stimulate PRA in monkeys (marmo-
set, Callithrixjacchus) [32]. These observations have contributed
to the general impression that the RAS probably does not play an
important role in CsA toxicity in humans [3—5]. Less appreciated
are the observations that CsA markedly elevates plasma total
renin and pro-renin concentrations [8, 33] and enlarges the JGA,
as in the patients presented in this Forum. "Striking" JGA
hyperplasia has been reported in heart transplant recipients
receiving CsA [8, 9]. In renal transplant recipients, conversion of
therapy from CsA to azathioprine dramatically reduces the num-
ber of renin-containing cells in the JGA of the grafted kidney [7].
The striking increase in secretion granules in these renin-
containing cells in humans is not reflected by a concomitant
increase in PRA. The lack of rise in plasma renin activity raises
the possibility of an alteration in cellular renin processing and in
the release of active renin. Indeed, clinical studies have demon-
strated a markedly blunted PRA secretoly response to a low-
sodium diet and diuretic administration in CsA-treated renal
transplant recipients [31] or to acute converting enzyme inhibition
in CsA-treated cardiac transplant recipients [34]. In insulin-
dependent diabetic patients, CsA is also associated with juxtaglo-
merular cell hypertrophy and a reduced renin secretory response
to furosemide [35].
A similar renin secretory defect also can develop in CSA-
treated rats. Burdmann et al found that ACE inhibition in
CsA-treated rats did not produce an anticipated increase in PRA
[36]; this observation is consistent with the possible presence of a
defect in renin secretion. A CsA-induced renal renin secretory
defect is more convincingly demonstrated in the rat under condi-
tions of maximal renin-axis activation. Helmchen and associates
examined the effect of CsA on renal renin content (RRC) and
plasma renin content (PRC) in two-kidney, one-clip hypertensive
rats [37]. Cyclosporine dramatically decreased the PRC (48.6
3.0 versus 82.2 5.0 [vehicle controll nglml/hr) and markedly
increased RRC in both the clipped (49.2 8.0 versus 11.9 1.0
jtg/100 mg/hr) and the intact (23.3 3.1 versus 1.7 0.4) kidney.
The study also noted morphologic evidence of increased JGA
activation [37].
The mechanism for this CsA-induced intrarenal renin accumu-
lation is not clear. Early observations suggest that CsA reduces
the conversion of pro-renin into active renin [8, 13], the usual
form of renin secreted through the regulated pathway. Cyclospor-
me also can directly block renin secretion, as it inhibits exocytotic
degranulation in a number of cell systems, possibly through its
inhibitory effect on the phosphatase activity of calcineurin [38, 39].
More recently, Norling and associates reported the progressive
accumulation of an acidic renin isoform (p1 5.5, MW 32—36 kD)
in the kidneys of CsA-treated rats [40]. Since acidic renin isoforms
normally constitute only a small fraction of the stored renin [41],
its accumulation suggests the presence of one or more CsA-
induced renin processing and trafficking defects. An increase in
the acidic forms of renin correlates with an elevation in systolic
blood pressure in stroke-prone hypertensive rats [42].
In summary, GsA has multiple effects on the RAS. First,
evidence is convincing for its direct stimulatory action on renin
synthesis and release in cultured juxtaglomerular cells. In addition
to this short-term response, CsA also causes a more sustained
response characterized by JGA hypertrophy and hyperplasia.
Finally, CsA induces alterations in renin processing and secretion,
reflected by increases in renal renin content and renin granule
accumulation, and by decreases in plasma renin content (in
humans). Are these effects the consequences of different mecha-
nisms or, more likely, do they represent different facets of a single,
complex process? The answers remain to be determined.
Differences in experimental and human peripheral renin
profiles
Much has been written on the dissimilarity in the RAS'
response to CsA in experimental and human studies. But the only
major difference is the level of circulating PRA (Table 1). In
experimental studies, both active and inactive renins increase
(Pattern I); in human and primate studies, only the inactive renin
increases (Pattern II). Two possible, but not mutually exclusive,
mechanisms could account for the evolution of these different
patterns.
Multiple sites of action of CsA on juxtaglomerular cells. Cyclo-
sporine acts on the juxtaglomerular cell's renin synthetic and
secretory process at three possible steps: stimulation of pro-renin
synthesis, inhibition of pro-renin-active renin conversion, and
blockade of active renin secretion (Fig. 2). The relative potency of
action at each site varies under different experimental conditions,
for example, the animal species used, and the duration and dosage
of CsA treatment. Thus, under short-term, in-vitro incubation
conditions, and in most animal studies, the greatest action is on
stimulation of pro-renin synthesis, whereas the inhibitory action
on pro-renin-to-active renin conversion or on active renin secre-
tion, if present, is relatively minor and inapparent (Fig. 2, upper
panel). The net effect of these actions can account for a Pattern I
renin profile in the circulation.
In more long-term human and primate studies, the inhibitory
effect of CsA on pro-renin-to-active renin conversion and the
secretion of active renin might dominate its stimulatoiy action on
pro-renin synthesis (Fig. 2, lower panel). The constitutive pro-
renin secretory pathway remains intact or minimally inhibited
[38]. This hypothesis would explain the finding of low PRA and
high pro-renin in the circulation of humans and primates, the
Pattern II profile. Circulating pro-renin can be further augmented
by pro-renin released from extrarenal tissues, while circulating
active renin can be further inhibited by CsA's effect on renal
hemodynamics resulting in sodium retention and volume expan-
sion [141.
Not all experimental studies yield a Pattern I renin profile.
Although PRA was consistently elevated in rats treated with CsA
for two weeks [16], when the treatment was prolonged to two
months, an elevation in PRA was no longer evident (unpublished
observation). Burdmann et al found that PRA was significantly
higher in CsA-treated rats when compared to vehicle-treated rats
at two weeks, hut by four weeks, the PRAs in the CsA-trea ted and
control rats no longer differed [36]. lntrarenal renin mRNA did
not increase in rats treated with CsA for three weeks [21]; this
finding suggests that this treatment regimen did not raise the
renin synthesis rate. In addition to the duration of the treatment,
varying the dosage of CsA also can exert a biphasic effect on PRA.
Siegl et al found that CsA caused a dose-dependent stimulation of
PRA up to 20 mg/kg/day. Further increases in dosage were
associated with a return of PRA to baseline levels [43]. Thus,
increasing the duration or dosage of CsA can change the renin
profile in animal studies from Pattern I to Pattern II. Likewise,
although most clinical studies have found circulating renin con-
forming to the Pattern II profile, some studies have reported a
Pattern I profile in GsA-treated patients [33, 44, 45]. Thus, under
Pattern II
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Fig. 2. Possible actions of cyclosporine (CsA)
on juxtaglomerular apparatus (JGA) renin
synthesis and secretion.
Fig. 3. Sources of circulating active renin and
pro-renin. cRAS = circulating renin-
angiotensin system; JGA = juxtaglomerular
apparatus; tRAS = tissue renin-angiotensin
system.
certain conditions, human RAS might respond to CsA in a fashion
similar to that of the animal RAS.
C'yclosporine acts on circulating as well as tissue R.4S. The RAS
comprises two components: the classical circulating (cRAS) and
the relatively recently recognized tissue (tRAS) components [46].
The eRAS consists of angiotensinogen, which is secreted by the
liver into the circulation, where it is cleaved by renin derived from
the kidney to form angiotensin I. Angiotensin I then is converted
by the angiotensin-converting enzyme in the pulmonary vascula-
ture into angiotensin II, which circulates to various tissues, where
it exerts its effects through interaction with angiotensin TI recep-
tors. Thus, the cRAS functions as a classical endocrine system,
and its activity traditionally is monitored by measurement of the
circulating renin activity, the PRA. Conventional practice classi-
fies a disorder as "high-renin" and "renin-dependent" if the PRA
is abnormally high, and "low-renin" or "renin-independent" if the
PRA is low.
The early phase of experimental renovascular hypertension is a
classic example of a renin-dependent disorder with a high PRA
[47]. Constriction of one renal artery produces a parallel rise in
blood pressure and PRA. Blockade of the RAS abrogates the
hypertension. However, if the renal artery constriction is sus-
tained chronically, the PRA falls to normal or below normal [47,
48]. Nevertheless, the hypertension persists and remains "renin-
dependent," that is, it continues to respond to maneuvers that
block the RAS. The observed changes in PRA might reflect a
"switch" from an initial activation of the eRAS to a more
sustained activation of the tRAS. Because the circulating active
renin is derived exclusively from the eRAS component of the
kidney (Fig. 3) [46], a fall in PRA would be anticipated when the
acute activation of the eRAS is replaced by the chronic activation
of the tRAS.
Evidence is accumulating that supports the existence of a local
tRAS whose activity is not reflected by PRA levels. The biologic
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Table 2. Diabetes mellitus and the renin-angiotensin system (RAS)
Low-renin syndrome
Low PRA and high renal renin content
High plasma pro-renin
Pro-renin correlates with microvascular damages
High incidence of hypertension
High incidence of renal damage
Affhrent arteriolopathy
Intrarenal RAS mediates renal injury
role of tRAS, particularly in terms of blood pressure homeostasis,
is highlighted by the recent generation of transgenic rats harbor-
ing the mouse Ren2d renin gene [TGR(mREN2)271 [49]. These
rats develop fulminant hypertension, low PRA, suppressed renal
renin content, high plasma inactive renin, and high extrarenal
transgene expression. These findings are not unlike those induced
by CsA. Angiotensin-converting-enzyme inhibition in this model
reproducibly reduced blood pressure by 40 to 60 mm Hg [50].
Proteins and messenger RNA encoding all the components of the
classical cRAS, including angiotensin receptors, have been co-
localized within many tissues, including the kidney, brain, adrenal,
pituitary and reproductive tissues, and the heart and vasculature
[46]. The kidney, although a major participant in the cRAS, has in
addition its own complete system of tRAS [51].
Cyclosporine clearly activates the cRAS in animals, as reflected
by its stimulatory action on PRA both in in-vitro and in-vivo
studies. In addition, CsA appears to stimulate the tRAS, as
evidenced by its activation of the different components of the RAS
in the vasculature [52], the kidney, the liver, and the adrenals [28].
Thus, like experimental renovascular hypertension, CsA stimu-
lates both the eRAS and the tRAS. I would argue that the
elevated PRA reported in most of the animal studies (Pattern I)
probably represents the early cRAS-stimulatory phase, while the
suppressed PRA observed in most human studies (Pattern II)
probably represents the chronic tRAS-stimulatory phase.
Diabetes mellitus: A CsA-like low-renin state
yclosporine's effects on the RAS and the microvasculature
closely resemble the hemodynamic and hormonal abnormalities in
diabetes mellitus (Table 2). Diabetes mellitus has been classified
as a low-renin condition because PRA is low in the circulation.
Nevertheless, the role of RAS in the microvascular damage seen
in diabetes is well established [53, 54]. Most studies in experimen-
tal as well as in clinical (type-I and type-Il) diabetes report normal
or low PRA in the circulation [53]. Renal renin content, on the
other hand, is disproportionately high; this finding suggests an
impairment in renal renin release into the circulation [54, 551. As
in the CsA studies cited earlier, plasma pro-renin is elevated in
diabetic patients, particularly in those with microvascular damage
[56, 57].
Relatively little is known about the function of pro-renin.
Pro-renin-activating enzymes have been found in the aorta and in
cultured endothelial cells [58]; these findings suggest that the
circulating renin precursor acts as a reservoir for the local
activation and amplification of the RAS activity in the blood
vessel. MUller-Schweinitzer, using canine saphenous veins, also
concluded that the vascular effect of CsA is the consequence of
activation of circulating pro-renin rather than the result of the
action of one or more angiotensin-forming enzymes located in the
venous vessel wall [52]. Sealey et al proposed that pro-renin can
be activated by binding at local tissue sites without cleavage of the
pro-sequence [591; this form of activation can lead to the local
generation of Ang II.
In long-standing diabetes mellitus complicated by microvascu-
lar disease, plasma inactive renin is high, and plasma active
pro-renin is normal or low [53—57]. Luetscher and colleagues
reported that the frequency of vascular complications (retinopa-
thy and albuminuria) varied directly with plasma inactive renin:
patients with plasma inactive renin of less than 20 ng/ml'/hr,
above 50 nml1/hr', and more than 100 ngIml/hr1 exhib-
ited these complications at a frequency of 0%, greater than 50%,
and greater than 95%, respectively [56]. Myers and associates
reported the mean value of plasma inactive renin in heart
transplant recipients with CsA-associated chronic nephropathy to
be 224 ng/ml/hr' [8]. Whether microvascular disease associ-
ated with CsA therapy correlates with plasma pro-renin levels has
not been studied.
Finally, diabetes mellitus, like CsA administration, is accompa-
nied by a high incidence of hypertension and renal injury associ-
ated with afferent arteriolopathy [53]. In diabetes mellitus, evi-
dence now implicates the local renal tissue RAS in the
pathogenesis of renal injury [53, 51.
RAS in CsA-induced hypertension and nephrotoxicity
cyclosporine-induced hypertension. Multiple mechanisms have
been proposed for the hypertensive effects of CsA [4, 14, 60],
including the possibility that several events and systems interact to
generate alterations in blood pressure. The role of the RAS is
most effectively demonstrated under controlled conditions in
which a relatively "pure" CsA hypertension can be induced. We
[16] and others [43, 61] have reported that spontaneously hyper-
tensive rats (SHR) predictably respond to CsA by a dramatic
exacerbation of hypertension, associated with marked increases in
PRA and pro-renin. Concomitant administration of enalapril
completely reversed this CsA-exacerbated hypertension [16].
More recently, Clozel, Fischli, and Ménard demonstrated that
ACE inhibition with colazapril and renin inhibition with Ro
42—5892 completely suppressed plasma Ang II and ameliorated
CsA-induced hypertension in monkeys [62], a model in which
CsA, as in humans, does not elevate PRA. Similarly, renin
antibodies suppressed circulating Ang II without reducing blood
pressure. This disparity was attributed to the inability of the
relatively large antibodies to diffuse out of the vasculature anti
inhibit local angiotensin generation. Thus, the tRAS likely partic-
ipates in the pathogenesis of CsA-induced hypertension.
The role of the renin axis on CsA-associated hypertension in
humans, as reflected by the blood pressure response to renin-axis
blockade, is less straightforward. The finding of low PRA in
CsA-treatcd patients and the concern over possible ACE inhibi-
tion-induced hypcrkalcmia and acute renal failure have led to the
avoidance of ACE inhibitors and the use of calcium-channel
blockers [41. Mourad, Ribstein, and Mimran reported a prospec-
tive, randomized 30-month study comparing the effects of lisino-
pril and nifedipine in the treatment of hypertension in CsA-
treated renal transplant recipients [631. They concluded that
lisinopril was as effective as nifedipine in the control of hyperten-
sion in these patients. Only 2 of the 14 lisinopril-treated patients
required furosemide as a second drug for adequate control of
hypertension; 7 of the 11 nifedipine-treated patients needed a
second drug, atenolol, for alleviation of a side effect (flushing) or
254 Nephrology Forum: CsA and the renin-angiotensin axis
for adequate blood pressure control. No relationship was ob-
served between ACE inhibition and renal functional deterioration
and hyperkalemia. In contrast to calcium-channel blockade, ACE
inhibition was associated with a significant reduction in the
filtration fraction and a decrease in the intraglomerular capillary
pressure. The effect of ACE inhibitors on hypertension appeared
to increase with the duration of drug administration [63]. Acute
ACE inhibition with captopril caused a smaller decrement in
blood pressure than did acute calcium-channel blockade with
nifedipine in CsA-treated, hypertensive heart transplant recipi-
ents [34]. The blood pressure response to calcium-entry blockade
can be mediated through the RAS. Thus, CsA potentiates the
action of Ang II on vascular smooth muscle cells [64], and
calcium-entry blockade can prevent this CsA-induced hypersensi-
tivity to Ang II [65].
Most likely, RAS activation is only one of many components in
the pathogenesis of CsA-induced hypertension [4, 14, 601. We
have noted that the hypertensive effect of CsA is most apparent in
a rat population genetically susceptible to hypertension [66].
Cyclosporine significantly worsened hypertension in the SHR but
did not increase blood pressure in the normotensive Sprague-
Dawley (SD) rat. Cyclosporine also increased blood pressure in
Wistar-Kyoto (WKY) rats that have higher than normal baseline
blood pressure [66], but had no hypertensive effect in Wistar-
Kyoto rats that have normal baseline blood pressure [61]. Other
groups also have observed that normotensive rats are relatively
resistant to the hypertensive effect of CsA [67, 68]. An inter-
species difference in response to CsA's hypertensive effect became
apparent when, in contrast to findings in the rat, CsA consistently
caused hypertension in normotensive marmosets [321. It is not
clear why virtually all heart transplant recipients appear suscep-
tible to the hypertensive effect of CsA, while recipients of other
organs and patients given CsA for conditions unrelated to trans-
plantation exhibit less susceptibility [4]. Bone marrow transplant
recipients, children [69] as well as adults [70], appear to be more
susceptible to severe hypertension when given CsA.
GsA nephrotoxicily. Several clinical and morphologic forms of
CsA nephrotoxicity have been described [3, 5]. Of greatest
concern to nephrologists is the progressive, irreversible tubuloin-
terstitial fibrotic form characterized by afferent arteriolopathy,
interstitial fibrosis (the so-called "striped" fibrosis), and some-
times by glomerular and arteriolar thrombi [3, 711.
Cyclosporine stimulates rabbit renal fibroblast production [72]
and increases collagen production both in human and animal renal
cell lines [73, 74]. Nast and associates have demonstrated an early
and sustained increase in cortical al(I) pro-collagen mRNA in
renal tissue of CsA-treated rats [75]. Perhaps CsA induces renal
fibrosis directly or indirectly, or both. We will focus on evidence
suggesting the participation of the RAS in this process.
Myers and colleagues proposed that chronic CsA therapy in
heart transplant recipients causes an obliterative arteriolopathy of
the afferent arterioles that leads to irreversible downstream
structural damage [76]. Three-dimensional morphometric analysis
of renal tissue revealed a marked deviation in the glomerular
capillary tuft volume distribution pattern in CsA-treated heart
transplant recipients [9] and in rats with a renal isograft [77]. In
control tissue, the capillary tuft volume was normally distributed
around the mean (bell-shaped curve), hut the CsA-treated tissue
had a relative increment in the number of glomeruli that were
either smaller or larger than the mean volume. The smaller
glomeruli possibly reflected CsA-induced ischemic damage and
capillary collapse, while the glomeruli unaffected by the ischemic
injury enlarged.
Mason and associates proposed that accumulation of renin in
the JG cells might cause arteriolopathy [13]. The lesion develops
in distal afferent arterioles as they enter glomeruli, where renin
production is most abundant and where renin accumulates with
CsA therapy in humans and animals. The lesion is characterized
by early vacuolation of the endothelial and smooth muscle cells,
followed by necrosis and proteinaceous deposits. Ultimate occlu-
sion and obliteration of the arteriole cause ischemic collapse and
fibrosis of the corresponding glomerulus and the associated
tubulointerstitium, and inflicts the greatest damage to the region
most vulnerable to reduction in oxygen supply, that is, the inner
stripe of the outer medulla and the medullary rays [78]. The
medullary rays are cortical invaginations of medulla extending
towards the capsule and consisting of collecting tubule, ascending
limb, and S2 and S3 proximal tubules. The striped appearance
described in CsA-treated humans and animals [71, 79] is attrib-
uted to the fibrosis of this medulla/medullary ray complex.
The spontaneously hypertensive rat was the first experimental
model to develop human-type afferent arteriolopathy with CsA
therapy. Electron microscopic examination of the kidneys in these
rats revealed increased accumulation of intracellular renin gran-
ules [61]. In subsequent studies, similar arteriolar lesions with
hyaline deposits have been produced in normotensive rats [80, 81]
and in rabbits [82]. In salt-depleted, Sprague-Dawley rats, the
CsA-induced "hyaline" injury in the smooth muscle cells corre-
lates with intracellular renin granule accumulation [81]. Enalapril
and losartan were found to reverse the rapid and sustained
afferent arteriolar vasoconstriction caused by CsA treatment in
these rats.
In addition to the juxtaglomerular apparatus and vascular
renin, the local, intrarenal RAS also might participate in the
pathogenesis of CsA nephrotoxicity. The inner zone of the outer
medulla has the highest density of angiotensin II receptors (AT1
subtype) [83], both in rat and human kidneys. Ultrastructural
studies localized the receptor to the interstitial cells between the
tubules and the vasa recta bundles. These cells exhibit character-
istics of type-i interstitial cells [84]. Because type-i interstitial
cells are most abundant toward the tip of the inner medulla, which
has almost no Ang II receptor-binding activity, these Ang II
receptor-rich cells are considered a subtype of type-I interstitial
cells. These medullaiy receptor sites are not easily accessible to
circulating Ang II and are more likely to respond to Ang II
generated in the kidney [83]. In addition to its traditional role of
stimulating vasoconstriction and aldosterone secretion, Ang II is
also an important growth factor [85]. Chronic infusion of Ang II
has been shown to cause renal interstitial cell proliferation and
fibrosis [86].
Young and associates have reproduced human-type CsA-in-
duced nephropathy in salt-depleted, male Sprague-Dawley rats;
the lesions comprised striped tubulointerstitial fibrosis, afferent
arteriolar hyalinosis, and increased JGA renin expression [87].
Fibrosis was preceded by tubular and interstitial cell proliferation
and macrophage infiltration, which in turn correlated with in-
creased expression of osteopontin at the same sites. Osteopontin,
a glycoprotein containing the RGD (Arg-Gly-Asp) sequence, is
chemotactic and adhesive for macrophages [881. In a model of
Ang Il-induced hypertension, renal tubulointerstitial injury also
evolved at sites of osteopontin overexpression and monocyte/
macrophage accumulation [89]. The authors postulated that CsA
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Fig. 4. Cyclosporine (CsA) and the refill-
angiotensin system (RAS) in the pathogenesis
of renal striped fibrosis (nephrotoxicity). Ang
TI = angiotensin II. 'Inner stripe of outer
medulla; **lnfiltration and proliferation:
***Ameliorated by ACE inhibition and
losartan.
directly activates intrarenal RAS, which then stimulates osteopon-
tin expression, macrophage infiltration and release of growth
factors, and increased extracellular matrix deposition and striped
cortical interstitial fibrosis [87].
Burdmann and associates have demonstrated that the tubulo-
interstitial fibrosis induced by CsA in rats kept on a low-salt diet
can be ameliorated by coadministration of an ACE inhibitor,
enalapril, or an angiotensin IT receptor antagonist, losartan [36].
Other, earlier studies also have reported a reduction in CsA
nephrotoxicity with converting enzyme inhibition therapy [90, 91].
Let me summarize how cyclosporine administration induces
striped fibrosis in the kidney (Fig. 4). Cyclosporine can induce
renal fibrosis directly (pathway #1) or indirectly through either
JGA and vascular renin accumulation (pathway #2) or stimula-
tion of intrarenal RAS (pathway #3). The activation of local Ang
II receptors can stimulate fibrogenesis directly (pathway #4), or
through the overproduction of osteopontin (pathway #5).
As in the case of CsA-induced hypertension, additional factors
and systems are likely to participate in the pathogenesis of
CsA-induced nephrotoxicity. Gillum and Truong did not find that
ACE inhibition protected against CsA-induccd tubulointerstitial
disease [92], although the CsA dose used (25 mg/kg intraperito-
neally for 28 days) was higher than that used by Burdmann (15
mg/kg subcutaneously for 28 days) [36] or Lafayette (9 mg/kg/day
orally for 12 months) [91]. The role of the RAS in renal fibrosis is
likely to be more complex than we now understand. For example,
both enalapril and losartan ameliorate CsA-induced fibrosis, but
only losartan, not enalapril, blocked the CsA-induced elevation in
cortical ol(l) pro-collagen mRNA [36]. It is likely that multiple
Ang Il-mediated pathways—for example, cell activation, cytokine
release, and matrix production—participate in the mediation of
CsA-induced nephrotoxicity.
QUESTIONS AND ANSWERS
DR. ALAN WIlKINsoN (Medical Director, Kidney and Pancreas
Transplantation, UCLA Medical Center, Los Angeles, California): I
have a question for Dr. Arthur Cohen. Most of the biopsy reports
we see are from patients who have had renal transplants. There is
still some debate as to whether the pathologic effects of cyclo-
sporine A differ in these kidneys as compared to effects in
non-transplant patients receiving cyclosporine for the treatment
of other diseases. You often call us when you see significant JGA
hypertrophy to inquire whether we suspect renal artery stenosis.
Do you see JGA hypertrophy less frequently in renal allografts
than in native kidneys exposed to cyclosporine?
DR. COHEN: In my experience, cases of enlarged juxtaglomer-
ular apparatus are not more frequent or more prominent in
transplanted than in native kidneys. The question of renal artery
stenosis is raised in transplants because of two considerations: (1)
the well-known fact that renal artery stenosis can be a complica-
tion of the arterial anastomosis or of arterial rejection, usually
chronic, involving the main or large renal arteries, and (2) the
common co-existence in the transplanted kidney of zones of
reduced tubular diameters with variable interstitial fibrosis, fea-
tures that are often part of the structural abnormalities of renal
artery stenosis.
DR. WILKINSON: Dr. Lee, ACE inhibitors as well as calcium-
channel blocking agents are effective in the treatment of post-
transplant hypertension. Calcium-channel blockers also might
confer a measure of protection against cyclosporine nephrotoxie-
ity. Do you have any information on the effect of calcium-channel
blockers on tissue renin concentration?
DR. LEE: I am not aware of any observations on the effect of
calcium-channel blockers on the concentration of tissue renin in
CsA-treated animals or patients. However, we do know that
calcium entry blockers stimulate, and calcium entry "facilitators"
inhibit, renin in studies using juxtaglomerular cells, renal glomer-
uli, renal cortical slices, and whole kidneys [93]. These responses
are consistent with the general observation that renin secretion is
inversely related to the ambient calcium concentration. Renin and
parathyroid hormone are two exceptions to the more typical
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secretory mechanism, in which the secretory rate correlates
positively with the intracellular calcium concentration [941.
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): My question
concerns the reliability of enzymatic assays for different compo-
nents of the renin system. Monoclonal antibodies recently have
been used for this purpose. Can you comment on their use in the
measurement of total, active, and inactive renins? Are there
studies on the effects of cyclosporine on the renin system that have
used specific monoclonal antibodies?
DR. LEE: The recently developed immunoradiometric assay of
renin using monoclonal antibodies allows direct measurement of
the active and inactive forms of the enzyme [95]. Compared to the
traditional enzymatic assay, it is simpler to perform, can be
completed within one working day, and exhibits greater inter- and
intra-laboratory reproducibility [96]. However, for clinical and
experimental applications, the enzymatic assay still might prove
more reliable and useful than the direct renin assay, particularly in
conditions associated with marked alterations in angiotensinogen
concentrations, for example, pregnancy or primary aldosteronism
[96]. The enzymatic assay measures the activity of endogenous
plasma renin and renin substrate (angiotensinogen) to form
angiotensin I in plasma. Because angiotensin-converting enzyme,
which converts angiotensin Ito angiotensin II, is not rate-limiting,
the enzyme method reflects the capacity of a patient's plasma to
generate the active hormone, angiotensin II. Thus, the enzymatic
assay gives a better reflection of circulating in-vivo activity of the
renin system. Finally, I am not aware of data on the effect of CsA
on the renin system based on measurements using monoclonal
antibodies.
DR. WILKINSON: You have developed a very nice hypothesis.
Can you fit the data from Luke and Curtis [14] into your schema?
They have shown that in hypertensive renal transplant patients
whose hypertension is salt-dependent, ACE inhibitors and bilat-
eral nephrectomy of the native kidneys each produce a similar
reduction in systemic blood pressure and about 30% improvement
in renal plasma flow and GFR of the transplanted kidney. This
observation implies that the retained native kidneys still exert an
effect on salt retention, blood pressure, and on the effective renal
plasma flow and GFR of the grafted kidney.
DR. LEE: One can postulate that allograft vasoconstriction
caused by renin release from the native kidneys is the primary
event. Bilateral nephrectomy or ACE inhibition then would be
expected to reverse the abnormalities you cited. Possible partici-
pation, or lack of participation, of CsA in the modulation of the
renin-angiotensin system in these complicated patients would
require more detailed studies.
DR. MADIAS: A captopril challenge test was introduced in the
late 1970s to differentiate among causes of post-transplant hyper-
tension. To what extent has the introduction of CsA affected the
utility of this test?
DR. LEE: In the "pre-CsA" era, a captopril-induced reduction in
allograft GFR was used as a screening test for the presence of
renal artery stenosis [4, 14, 97]. The sensitivity of the test is
increased by pre-treatment with a diuretic. A positive captopril-
challenge test is also observed with chronic vascular rejection, in
which small intrarenat vascular lesions can induce an angiotensin
Il-dependent efferent vascular constriction [4, 14, 97]. The intro-
duction of CsA as a routine therapy for transplant recipients,
markedly reduced the diagnostic usefulness of this test. Captopril
and other ACE inhibitors can markedly reduce GFR in CsA-
treated allograft patients in whom either renal artery stenosis nor
vascular rejection is present [4, 14, 97, 98]. This is hardly
surprising since, as we have just discussed, CsA can directly
stimulate both the circulating and the intrarenal RAS to generate
angiotensin II. The effect of ACE inhibition on GFR is expected
to be magnified in patients with concomitant CsA afferent arte-
riolopathy. Parenthetically, CsA has been reported to cause
reversible stenosis of major brances of the renal artery in renal
allograft [99].
DR. MADJAS: Is cyclophilin found in the juxtaglomerular appa-
ratus?
DR. LEE: Cyclophiliri is found in almost all organisms and cell
types and is the leading candidate for the receptor responsible for
the biologic effects of CsA [100, 101]. The renin stimulatoiy effect
of CsA in isolated juxtaglomerular cells was attributed to its
binding to cyclophilin, because cyclosporine H (CsH), which binds
cyclophilin weakly, did not affect renin secretion [20]. Quantita-
tive immunofluorescence and confocal microscopy have demon-
strated in rat kidneys the presence of cyclophilin, which increased
with CsA administration [101]. An examination of different
isoforms of cyclophilin using murine renal tissue revealed a
restricted distribution of cyclophilin C to proximal straight tubule
[102, 103] and proximal convoluted tubule [103]; cyclophilin A
was more evenly distributed along the nephron segments [103].
Cyclosporine A treatment increased the cyclophilin C signal [100].
I am not aware of any specific attempts at demonstrating the
presence of cyclophilin in the juxtaglomerular apparatus.
DR. IRA KURTZ (Chief Nephrology Division, UCLA Medical
Center, Los Angeles): Not only is CsA nephrotoxic, but it also
affects the liver, pancreas, and heart. What is known about the
extrarenal tissue renin-angiotensin system in these organs? Does
the RAS have a role in the abnormal function of these organs as
it does in the kidney?
DR. LEE: The effects of CsA on the tissue renin-angiotensin
system in the liver, pancreas, and heart have not received much
attention. Cyclosporine has been reported to upregulate angio-
tensin receptors in the liver, and this effect is blocked by lisinopril
and losartan (DUP 753), an angiotensin receptor antagonist [281.
This is a good question and deserves further exploration.
DR. MADIAS: You showed data on cardiac transplant patients
indicating that those receiving azathioprine had substantially
higher PRA levels than those receiving CsA. Could you review the
data on what happens to PRA in renal transplant recipients after
they are converted from CsA to azathioprine?
DR. LEE: The effect of CsA on PRA in most studies is
documented by comparing PRA in CsA-treated patients with that
in non-CsA (usually azathioprine)-treated patients. In a recent
report, 18 renal transplant patients were studied both before and
16 weeks after conversion from CsA to azathioprine [104]. Plasma
renin concentration rose from 27.7 12.4 .tU/ml to 34.7 12.2
U!ml before and after discontinuation of CsA, respectively. This
change did not attain statistical significance, however.
DR. CLAUDIA LANDIS (Nephrology Section, VA Medical Center,
West Los Angeles): My comment relates to the renin secretory
pathway. Perhaps pro-renin is secreted constitutively and active
renin through the regulated pathway, and possibly CsA inhibits
only the regulated secretory pathway, leaving the pro-renin secre-
tory pathway intact. This could lead to the pattern of low active
renin and high pro-renin you find in the circulation of CsA-treated
patients.
DR. LEE: The pro-renin that comes out of the Golgi apparatus
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is directed to one of the two secretory pathways: the regulated
pathway, which involves the processing of pro-renin to active
renin in the secretory granules prior to secretion, and the corlsti-
tutive pathway through which pro-renin is secreted without pro-
cessing. Evidence in extrarenal tissue also suggests that the
cellular release of pro-renin utilizes the constitutive secretory
pathway [1051. You have postulated a plausible explanation for
the peripheral renin profile in CsA-treated patients.
DR. MADIAS: Cyclosporine induces changes in a number of
other vasoactive substances, for example, endotheliri, nitric oxide,
atrial natriuretic peptide, and the prostanoids. Could you com-
ment on the contribution of these substances to the changes in
renin that you have described?
DR. LEE: As I mentioned, CsA affects a large number of
vasoregulatory agents, and each of these agents can interact with
the renin-angiotensin system. In this Forum I have tried to focus
roy discussion on the possibility that, in addition to modulating
renin activity indirectly through other vasoregulatory agents and
mechanisms, CsA also can act directly on the renin-angiotensin
axis.
DR. MAmAs: You mentioned that ACE inhibitors and Ang II
receptor antagonists ameliorate CsA-induced fibrosis. Might this
property be secondary, at least in part, to these drugs' effects on
CsA metabolism?
DR. LEE: As I recall, Burdmann and associates did not address
that possibility in their paper [361. However, I am not aware of any
data suggesting that the blockade of the RAS is associated with an
alteration in CsA metabolism.
DR. GLENN NAGAMI (Chief Nephrology Section, VA Medical
Center, West Los Angeles): What is the evidence that cyclosporine
directly alters renal cell components of the renin-angiotensin
system such as angiotensinogen, renin, and ACE? Is there any
evidence that CsA alters the expression of angiotensin receptors
in the kidney?
DR. LEE: I believe that the most convincing evidence for a direct
effect of CsA on renal renin metabolism is its stimulatory action
on renin synthesis and release in isolated juxtaglomerular cells
[20]. I know of no data on the effect of CsA on intrarenal renin
RAS outside the juxtaglomerular cells, but, as I mentioned, CsA
does modulate AT1 receptor expression in the kidney [21, 28].
DR. CHARLES R. KLEEMAN (Nephrology Section, VA Medical
Center, West Los Angeles): David, thank you for an excellent
synthesis of the information on cyclosporine and the renin system.
Would you comment on the role of calcium on renin secretion? I
thought you said that a high calcium level stimulates renin
secretion.
DR. LEE: I meant that calcium-channel blockers increase renin
secretion. In general, it is believed that a low calcium level
stimulates renin secretion.
DR. KLEEMAN: yclosporine causes salt retention. You have not
mentioned that important phenomenon in relation to the renin-
angiotensin system and the development of high blood pressure.
DR. LEE: Thank you for pointing out that changes in sodium
balance can both cause and be a consequence of changes in renin
axis activities. However, sodium retention as a cause of CsA-
induced hypertension remains controversial [4]. 1 believe the
point of your question is that CsA can cause changes in the renin
axis through multiple pathways and can induce hypertension and
nephrotoxicity via many mechanisms. I agree with you. As I said
earlier, in this Forum I have focused my remarks on the possibility
that CsA might act directly on the renin-angiotensin system, and
I raised the possibility that this action might constitute one
component in the pathogenesis of CsA-induced hypertension and
nephrotoxicity.
DR. JOEL D. KOPPLE (Chief Division of Nephrology and Hyper-
tension, Harbor/UCLA Medical Center, Los Angeles): Data suggest
that CsA also affects blood pressure by ways other than the RAS
system. Would you briefly comment on them?
DR. LEE: A host of agents and mechanisms have been proposed
in the pathogenesis of CsA-associated hypertension [4, 14, 60].
These include adrenergic hyperactivity, the vasoregulatory sys-
tems such as the eicosanoids and the kinins, endothelium-derived
factors, renal hemodynamics and function, and a direct vascular
effect of CsA.
DR. MAjIJAs: Does cyclosporine alter the vascular responsive-
ness to Ang II?
DR. LEE: Cyclosporine potentiates the action of Ang II on
vascular smooth muscle cells [64]; calcium entry blockade can
prevent this CsA-induced hypersensitivity to Ang II [65].
DR. KOPPLE: What is known about the effect of CsA on cytosolic
Ca2, both in acute and chronic states?
DR. LEE: In general, CsA increases cytosolic Ca2 concentra-
tion [Ca2 ] [106]. It is more difficult to explain the acute and
chronic effects of CsA on intracellular [Ca2] without getting
down to the specifics. Let us take the example of mesangial cells
[107]. Pre-incubation with CsA caused a small but significant
increase in basal cytosolic [Ca2] and a marked, up to fourfold,
increase in the vasoconstrictor-induced rise in peak levels and (in
the presence of external Ca) a more persistent post-peak elevation
in cytosolic [Ca2]. The time-dependent changes in the response
of intracellular [Ca2] to CsA would be expected to depend on
multiple factors.
DR. MADIAS: A number of vasoactive substances, for example,
angiotensin II, endothelin, and TGFI3, increase fibrosis by increas-
ing the synthesis of extracellular matrix proteins. They also can
decrease the degradation of collagen by inhibiting collagenase
activity. Is there any evidence that CsA affects collagen degrada-
tion?
DR. LEE: That is an interesting thought. I don't believe the idea
has been looked into in detail.
DR. NORIMOTO YANAGAWA (Associate Chief Nephrology Section,
VA Medical Center, Sepulveda): You mentioned an interesting
possibility, specifically, that CsA initially activates the circulating
renin-angiotensin system (eRAS) and later switches to activate the
tissue renin-angiotensin system (tRAS). I guess this is what
underlies the Pattern I and Pattern El responses to CsA, and I
wonder whether the trigger for this "switch" is the suppression of
active renin conversion and/or secretion. Do you know whether
the same mechanism occurs in other situations, such as in the
chronic phase of renal artery constriction and in diabetes mellitus,
where the Pattern II profile prevails?
DR. LEE: You have correctly pointed out that an evolution from
Pattern 1, high plasma active renin and high plasma pro-renin, to
Pattern II, normal or low plasma active renin and high plasma
pro-renin, peripheral renin profile has been observed in experi-
mental renovascular hypertension and also has been proposed to
occur in experimental diabetes mellitus [55]. I would propose that
CsA acts on juxtaglomerular cell renin metabolism at three steps:
(1) stimulation of pro-renin synthesis, (2) inhibition of pro-
renin—active renin conversion, and (3) blockade of active renin
secretion. In short-term experimental studies, the action on step I
appears to predominate, giving rise to a Pattern I renin profile.
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With more sustained or high-dose CsA treatment, the effect on
steps 2 and 3 overshadows that on step 1, while the constitutive
pro-renin secretory pathway remains intact, thus giving rise to a
Pattern II renin profile. Plasma pro-renin might be further
augmented by pro-renin release from extrarenal tissues, while
plasma active renin can be further reduced by the renal vasocon-
strictive effect of CsA with consequent sodium retention and
volume expansion.
DR. MADIAS: Low-renin essential hypertension is characterized
by disproportionately high levels of plasma aldosterone. Could
you please comment on the effects of CsA on plasma aldosterone?
DR. LEE: Experimental studies suggest that CsA does not affect
plasma aldosterone in the presence of a marked stimulatory effect
on plasma active renin and pro-renin [16]. This lack of effect is
attributed to the induction of a selective adrenal resistance to Ang
II, leaving the adrenal response to potassium and ACTH intact
[16, 1081. In clinical studies, CsA has been reported to increase
[109, 110], decrease [111, 1121, or cause no change [33, 113—115]
in plasma aldosterone. Clearly, CsA-aldosterone interaction is
another complex area for further investigation.
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